Related Experiment Video
Updated: Feb 27, 2026
07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
6.6K
Radiosensibilisierung durch BRAF Inhibitoren
Sophia Boyoung Strobel1, Sylvie Pätzold2, Lisa Zimmer3
1Abteilung für Dermatologie und Nationales Centrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
Summary
Combination therapy with BRAF inhibitors and radiation shows good local response in melanoma patients, with severe skin toxicity being rare and manageable. This approach remains a viable option for aggressive melanomas despite potential skin side effects.
Area of Science:
- Oncology
- Dermatology
- Radiation Oncology
Background:
- Recent literature highlights increased skin toxicities with combined BRAF inhibitor and radiotherapy.
- Melanoma treatment often involves targeted therapies and radiation, necessitating an understanding of combined treatment effects.
Purpose of the Study:
- To evaluate the efficacy and toxicity of combined BRAF inhibitor and radiotherapy in advanced melanoma.
- To assess the incidence and severity of skin toxicity in patients receiving this combined treatment.
Main Methods:
- Retrospective analysis of seven melanoma patients with unresectable Stage III or IV disease.
- Patients received combined treatment with radiation and a BRAF inhibitor (Vemurafenib or Dabrafenib).
Main Results:
- All patients achieved good local response with combination therapy.
- Severe radiodermatitis (CTCAE Grade 3 or 4) occurred in two patients receiving Vemurafenib, requiring treatment interruption.
- Mild skin reactions (CTCAE Grade 1 or 2) were observed in other patients, with one case of recall dermatitis after therapy completion.
Conclusions:
- Combined BRAF inhibitor and radiotherapy demonstrates good local response in advanced melanoma and is generally well-tolerated.
- Severe skin toxicities are infrequent and manageable, supporting the continued use of this combination therapy for aggressive melanomas.
- Sequential therapy does not appear to prevent toxicity reactions compared to concurrent treatment.
